SCHEMBL8777777

SCHEMBL8777777

COc1cc(S(N)(=O)=O)c(OC)cc1N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 1.00
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
P2RX3 P56373 1/20 0.45
P2RX2 Q9UBL9 1/20 0.45
CA2 P00918 5/20 0.44
CA1 P00915 4/20 0.44
CA12 O43570 4/20 0.44
CA9 Q16790 4/20 0.44
GAA P10253 1/20 0.44
CA4 P22748 1/20 0.42
S100B P04271 1/20 0.42
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP3A4 P08684 2/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30068292 1.00 PKM (1.00) PKMPOLBL3MBTL1P2RX3P2RX2
SCHEMBL9645148 0.88 PKM (0.79) PKMPOLBL3MBTL1P2RX3P2RX2
SCHEMBL7243296 0.86 PKM (0.75) PKMPOLBL3MBTL1P2RX3P2RX2
SCHEMBL7785291 0.85 PKM (0.73) PKMPOLBL3MBTL1CA2CA1
SCHEMBL8777836 0.85 PKM (0.73) PKMPOLBL3MBTL1P2RX3P2RX2
SCHEMBL29776125 0.85 PKM (0.73) PKMPOLBL3MBTL1CA2CA1
SCHEMBL11497077 0.83 PKM (0.71) PKMPOLBL3MBTL1CA2CA1
SCHEMBL11688578 0.83 PKM (0.70) PKMP2RX3P2RX2CA2CA1
SCHEMBL7764285 0.82 PKM (0.70) PKMPOLBL3MBTL1CA2CA1
SCHEMBL4650366 0.82 PKM (0.70) PKMPOLBL3MBTL1CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 US disclosed
EP-4337198-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2024-03-20 EP disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 US disclosed
CN-104403349-A Industrial production method of pigment yellow 97 CROWN CHEMICAL CO LTD 2015-03-11 CN disclosed
EP-0585873-B1 Method of preparing disazo pigments CLARIANT GMBH (DE) 1997-12-29 EP disclosed
US-5559216-A AZO COUPLING HOECHST AG (DE) 1996-09-24 US disclosed
US-5493011-A PIGMENTING HIGH MOLECULAR WEIGHT NATURAL OR SYNTHETIC ORGANIC MATERIALS HOECHST AG (DE) 1996-02-20 US disclosed
EP-0518909-B1 WATER-INSOLUBLE AZO DYES, THEIR MANUFACTURE AND USE HOECHST AG (DE) 1994-05-25 EP disclosed
EP-0585873-A1 Method of preparing disazo pigments HOECHST AKTIENGESELLSCHAFT (DE) 1994-03-09 EP disclosed
EP-0518909-A1 WATER-INSOLUBLE AZO DYES, THEIR MANUFACTURE AND USE. HOECHST AG (DE) 1992-12-23 EP disclosed
EP-0316649-B1 WATER INSOLUBLE AZO COLOURING AGENTS, THEIR PREPARATION AND USE HOECHST AKTIENGESELLSCHAFT (DE) 1992-07-22 EP disclosed
WO-1991013941-A1 WATER-INSOLUBLE AZO DYES, THEIR MANUFACTURE AND USE HOECHST AKTIENGESELLSCHAFT (DE) 1991-09-19 WO disclosed
US-5026831-A Water-insoluble disazo colorants having hetero-bicyclic methylene-active compounds as coupling component HOECHST AKTIENGESELLSCHAFT (DE) 1991-06-25 US disclosed
EP-0316649-A2 Water insoluble azo colouring agents, their preparation and use HOECHST AKTIENGESELLSCHAFT (DE) 1989-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 PKM 264/4885POLB 285/4885L3MBTL1 2917/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 PKM 264/4885POLB 285/4885L3MBTL1 2917/4885
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 PKM 264/4885POLB 285/4885L3MBTL1 2917/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 PKM 264/4885POLB 285/4885L3MBTL1 2917/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 PKM 260/4885POLB 271/4885L3MBTL1 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.